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Osteoclast differentiationA B S T R A C T
Charcot neuroarthropathy is a chronic, progressive condition of the skeletal system that
affects some patients with diabetic neuropathy. It results in progressive destruction of
bones of the foot and disorganisation of pedal joints and ligaments. Effective prevention
and treatment for Charcot neuroarthropathy remain a challenge. Currently, there are no
reliable repeatable markers to identify patients with diabetes who are at higher risk of
developing Charcot neuroarthropathy. The pathogenesis underlying the development of
Charcot neuroarthropathy also remains unclear. In this review, we provide an overview
of the history, prevalence, symptoms, risk factors, diagnostics and treatment of Charcot
neuroarthropathy. We also discuss the potential for OPG and RANKL gene variants to act
as predictive markers for the development of Charcot neuroarthropathy. Finally, we sum-
marise the latest research on the role of monocyte-to-osteoclast differentiation in the
development of acute Charcot neuroarthropathy.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
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the modern world, and its prevalence has reached epidemic
proportions [1]. Long-term and uncontrolled hyperglycaemia
leads to a number of severe consequences. The most com-
mon complication of diabetes is neuropathy which, accord-
ing to some sources, affects up to 60% of patients with
diabetes [2,3]. Neuropathy most often manifests as diabetic
foot syndrome with hard-healing ulcers. Some patients with
symmetrical distal neuropathy develop a chronic, and pro-
gressive condition called Charcot neuroarthropathy (CN),
also known as diabetic neuropathic osteoarthropathy
(DNOAP), Charcot foot or Charcot joint disease. It results in
the progressive destruction of bones of the foot and soft tis-
sues at weightbearing joints; in its most severe form, it may
cause significant disruption of the bone architecture [4,5].
The degree of bone destruction, subluxation, dislocation,
and deformity varies in the clinical picture of Charcot neu-
roarthropathy; neuropathy, trauma, and disturbances in
bone metabolism underlie this complication [4–7]. In Charcot
neuroarthropathy, the acute (or active) and chronic (or inac-
tive) phases are distinguished to describe the inflamed or
the stable phase in the clinical course of this condition,
respectively [8].
Although the number of reports on genetic studies on
Charcot neuroarthropathy and treatment guidelines have
increased in recent years, the exact molecular mechanism
of the disease remains unclear. Moreover, there are no effec-
tive therapies to prevent or inhibit its development. Here, we
provide a comprehensive overview of the history, prevalence,
symptoms, risk factors, diagnostics and treatment of Charcot
neuroarthropathy. We also discuss the association of OPG and
RANKL variants with Charcot neuroarthropathy. Finally, we
summarise the latest research on the role of monocyte-to-
osteoclast differentiation in the development of acute Char-
cot neuroarthropathy.
2. History
In 1703, William Musgrave first described a neuropathic joint
as an arthralgia caused by venereal disease [9]. The associa-
tion between nerve injury of different origins and arthropathy
was first mentioned in the nineteenth century by John Kears-
ley Mitchell [10], and the idea was further developed by the
French neurologist Jean-Marie Charcot [11]. The condition
was first described in association with venereal disease and
tabes dorsalis. Syphilis was believed to be the most common
cause of Charcot arthropathy until 1936, whenWilliam Jordan
first noted its relationship with diabetes [12]. Nowadays,
Charcot neuroarthropathy is predominantly observed inpatients with diabetes during the course of diabetic neuropa-
thy [8].
3. Prevalence, symptoms and risk factors
The reported incidence of Charcot neuroarthropathy in the
general population of patients with diabetes is around 0.16%
[13], and may be even higher in subjects with diabetic neu-
ropathy, where it may reach up to 29%. The prevalence is
reported to vary from 0.08% in the general population of
patients with diabetes to 13% in high-risk patients with dia-
betes and peripheral neuropathy [14,15]. It is usually unilat-
eral, but according to some sources it can affect both feet in
up to 75% of cases [16]. Mortality in patients with this compli-
cation is high, exceeding the mortality of some cancers such
as prostate or breast cancer [17].
The acute Charcot neuroarthropathy manifests as a triad
of symptoms: unilateral oedema, redness, and a local
increase in temperature. In some cases, slight pain is present.
The clinical picture resembles other aetiologies of swelling of
the foot, such as cellulitis, sprains or deep vein thrombosis;
therefore, the diagnosis is often difficult and delayed [4,7,8].
Chronic Charcot neuroarthropathy is easily recognizable with
the rocker-bottom appearance of the foot, resulting from irre-
versible deformation due to metatarsal collapse or joint
destruction [4,7,8]. These deformities predispose to skin
ulceration, an established risk factor for amputation [4].
The risk factors for the development of Charcot neu-
roarthropathy are not well understood. According to some
authors, the highest incidence of this complication is
observed in patients between 60 and 70 years of age with
a diabetes duration of more than 10 years [18]. However,
Petrova and colleagues observed a higher incidence of Char-
cot neuroarthropathy in patients with diabetes who were
aged in their 40 s and 50 s [19]. Type 1 and type 2 diabetes
differ with regard to diabetes duration and Charcot neu-
roarthropathy risk. When compared to patients with type
2 diabetes, patients with type 1 diabetes and Charcot neu-
roarthropathy tend to be younger, and these patients have
generally had diabetes for a longer time [19]. The risk factor
that is most strongly correlated with Charcot neu-
roarthropathy is social isolation. Nobrega and colleagues
suggest that acute Charcot neuroarthropathy primarily
affects patients aged under 55 years who live alone, are lit-
erate, and have a prior history of ulcers [20]. Peripheral
arterial disease is a protective factor [20]. Contradictory
results have been obtained regarding body mass index
(BMI); some studies report that obesity is associated with
an increased incidence of Charcot neuroarthropathy
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observed [20,23]. It is not clear whether low bone mineral
density (BMD) is a risk factor for the development of Char-
cot neuroarthropathy; the calcaneal BMD of patients with
diabetes and Charcot neuroarthropathy is lower compared
to healthy controls, but is similar between patients with
Charcot neuroarthropathy and patients with diabetes alone
[24]. A higher incidence and poorer outcome of this compli-
cation is observed in patients with diabetes and concurrent
renal disease [25]. Impaired renal function, haemodialysis,
peritoneal dialysis, and kidney or simultaneous kidney/pan-
creas transplantation correlate with the incidence and pro-
gression of Charcot neuroarthropathy [25–27].
4. Diagnostics
In the acute stage, Charcot neuroarthropathy is diagnosed
mainly on clinical grounds, supported by diagnostic imag-
ing. Plain foot radiographs are recommended as the initial
diagnostic method [3]. Radiographs allow for an overall
assessment of anatomy and the detection of bone destruc-
tion, dislocations and deformity of the foot, all findings that
are typical of advanced Charcot neuroarthropathy [28].
Unfortunately, plain X-ray films have low sensitivity for
diagnosing subtle, initial abnormalities within the skeletal
system, as X-rays in the very early stages of Charcot neu-
roarthropathy may appear normal. In the earliest stage of
Charcot neuroarthropathy, magnetic resonance imaging
(MRI) or nuclear medicine studies following initial X-rays
are recommended to confirm the acute bone pathology.
MRI is a highly sensitive imaging method that, in cases of
acute Charcot neuroarthropathy, allows the detection of
signs of bone marrow and soft tissue oedema, stress frac-
tures without cortical disruption and joint effusion [28].
Radionuclide imaging with labelled white cells may help
to differentiate Charcot neuroarthropathy from osteomyeli-
tis with a specificity of 80% and sensitivity of about 80%
[29]. Positron emission tomography-computed tomography
(PET-CT) may prove to be a valuable method for diagnosing
Charcot neuroarthropathy; however, due to its high cost
and limited availability, it is not widely applied. In the
chronic stage of Charcot neuroarthropathy, plain radio-
graphs show dislocation or subluxation, deformity, destruc-
tion, disorganisation, debris and increased subchondral
bone mineral density, known as the rule of ‘‘six Ds” [30].
At this stage, an intervention that would prevent gross
deformity of the foot is not usually possible.
At present, there are no reliable markers that could con-
firm the diagnosis of Charcot neuroarthropathy in its acute
phase. In addition, it is not possible to determine which
patients affected by neuropathy are at greater risk of develop-
ing this complication. It also remains unclear why this pro-
cess is unilateral and self-limiting in the majority of cases.
Due to the lack of typical laboratory and radiological charac-
teristics, acute Charcot neuroarthropathy is misdiagnosed
and mistreated in up to 25% of cases [31]. Diagnostic errors
resulting in improper or delayed treatment can lead to pro-
found deformity, an increased risk of ulceration or lower-
limb amputation. Acute Charcot neuroarthropathy is com-monly misdiagnosed as bacterial inflammation and phleg-
mon of the foot, which is referred for surgical intervention
[4]. Advanced cases with bone destruction evident on X-rays
are difficult to distinguish from osteomyelitis, especially if a
foot ulcer is present [32,33]. A careful patient history and
examination may aid in the diagnosis of acute Charcot neu-
roarthropathy [32]. A history of minor trauma, lack of previ-
ous (or present) ulcer, and a reduction of erythema upon
elevation of the leg are all characteristic features of Charcot
neuroarthropathy. Patients also display very dense neuropa-
thy and, in most cases, there is no foot ischemia [32]. Mea-
surement of uric acid levels and a negative venous Doppler
exam may help to exclude gout and deep vein thrombosis.
Levels of procalcitonin (PCT) and C-reactive protein (CRP), ery-
throcyte sedimentation rate (ESR) and leukocyte count are
usually normal [34].
5. Treatment
In the very early stage, Charcot neuroarthropathy is usually
treated with custom footwear, a cast shoe containing a
custom-made insole, or orthoses to protect the foot and ankle
[32]. Using this footwear effectively reduces swelling and pro-
tects the bones of the foot at risk from developing Charcot
neuroarthropathy. The gold standard of treatment of the
acute Charcot neuroarthropathy is non-weight bearing or a
reduction in weight-bearing and immobilisation of the
affected foot, preferably in a total contact cast [35]. Applica-
tion of this treatment modality requires expertise. Protective
padding should be applied between the toes, with additional
padding over bony prominences. The cast should be removed
regularly to assess possible wounds caused by friction while
the oedema resolves. The length of necessary immobilisation
varies between individuals, with one study reporting a mean
duration of casting as long as 18.5 ± 10.6 weeks [36]. A pro-
longed period of casting may result in overloading of the con-
tralateral foot, muscle wasting, a further reduction in bone
mineral density and increased body mass index. Offloading
should continue until the patient has entered the healing
phase, clinically defined as a reduction in oedema and a tem-
perature difference between the affected and contralateral
foot of less than 2 C [33,35]. The transition to weight-
bearing and regular activity of the patient must be gradual,
preferably supported by a physiotherapist; beginning strenu-
ous exercise too soon after removal of the total contact cast
may result in the recurrence of acute Charcot neuroarthropa-
thy. For long-term management of patients after weaning out
of the total contact cast, custom footwear or total contact
insoles are recommended to ensure that the foot is accommo-
dated and protected [32,37].
Surgical treatment of Charcot neuroarthropathy is recom-
mended for those patients who have severe ankle and foot
deformities that are unstable and at a high risk of developing
a foot ulcer [7]. If the deformity makes braces and orthotics
difficult to use, surgery may also be indicated. The clinical
outcome of a patient after surgical correction often results
in improved quality of life [38], but it may also be associated
with a high complication rate [39].
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are under study as an additional option to classical treat-
ments. These treatments include the administration of
antiresorptive agents (bisphosphonates and calcitonin), ana-
bolic agents (recombinant parathyroid human hormone), or
anti-RANKL monoclonal antibody (denosumab). However,
the clinical efficacy of these agents is still inconclusive (re-
viewed in [37,40]).
6. Pathogenesis of Charcot neuroarthropathy
The underlying pathogenesis of Charcot neuroarthropathy is
still not completely understood. Two main theories to explain
the pathogenesis of the condition have been described in the
literature: the neurovascular theory, and the neurotraumatic
theory. Michael E. Edmonds, in his study, observed that the
peripheral neuropathy was frequently accompanied by hyper-
aemia, which could result in osteopenia and, consequently,
bone fractures caused by even minor trauma (neurovascular
theory) [31]. Other authors associated the development of
Charcot neuroarthropathy with repetitive trauma acting on
a foot with sensory neuropathy (neurotraumatic theory)
[41]. It seems that the interaction of certain factors, such as
presence of diabetes, peripheral neuropathy (both sensory
and motor) and metabolic abnormalities affecting bone (os-
teopenia), are key factors in the pathogenesis of the disease.
A reduction in BMD is often reported in the affected foot com-
pared to the contralateral foot [42–45]. How immobilization
and off-loading therapy affects BMD is still inconclusive.
According to some authors, BMD falls over time in the
affected foot as casting therapy is introduced [45], while other
authors have shown no long-term effects of this therapy on
further BMD loss [46,47].
At the beginning of the twenty-first century, inflammation
was identified as a key component in the pathogenesis of
Charcot neuroarthropathy. The ‘‘inflammatory theory” stres-
ses the pathogenic importance of local ongoing inflammation
and the increased expression of proinflammatory cytokines,
including IL-1b, IL-6, TNF-a and other factors, in the patho-
genesis of Charcot neuroarthropathy [48,49]. The proinflam-
matory state is linked to the bone turnover observed in
Charcot neuroarthropathy. However, it is still unclear
whether it is the cause or the consequence of the ongoing
bone destruction process occurring in the affected foot. The
venous-arterial flux of IL-6 is increased in the affected foot
of patients with Charcot neuroarthropathy compared to the
healthy foot, suggesting that IL-6 is locally produced in the
affected foot [50]. Serum levels of TNF-a, IL-6 or C-reactive
protein are higher in patients with acute Charcot neu-
roarthropathy prior to treatment, with a decrease observed
following casting therapy, a standard treatment method for
Charcot neuroarthropathy [51]. Serum TNF-a or IL-6 have also
been reported to be positively correlated with C-terminal
telopeptide, a bone turnover marker, and serum osteoprote-
gerin (OPG) levels at presentation but not after casting ther-
apy [51]. Other studies suggest that activation of the
proinflammatory cytokines IL-6, IL-17 and TNF-a in patients
with Charcot neuroarthropathy occurs after they beginoffloading therapy, representing a key step in bone repair
and remodelling during recovery [52,53].
6.1. Role of the OPG-RANKL-RANK axis in bone resorption
and formation
The physiological balance between pro- and anti-
inflammatory cytokines plays an important role in the
course of Charcot neuroarthropathy. The release of proin-
flammatory cytokines leads to increased activity of the
metabolic pathway consisting of OPG, receptor activator of
nuclear factor jB (RANK) and its ligand, receptor activator
of nuclear factor jB ligand (RANKL). RANKL is the main fac-
tor in the bone matrix responsible for the differentiation of
osteoclast precursor cells and their activation to mature
osteoclasts [54]. It exists as a membrane-bound protein pro-
duced by osteoblast lineage cells and activated T cells, as
well as a soluble protein which can be detected in blood
serum [55]. As there are at least three isoforms of RANKL
mRNA, it is plausible that different forms of RANKL are pro-
duced from different mRNAs [56]. RANKL exerts its biological
activity through the RANK receptor, which is present on the
surface of preosteoclasts, mature osteoclasts and several
other cell types. Binding of RANKL to RANK initiates a signal
cascade within the cell, which involves the recruitment of
TRAF factors (TRAF2, TRAF5 and TRAF6) to the cytoplasmic
domain of RANK and results in the activation of nuclear
transcription factors NF-jB and JNK. This process leads to
the differentiation of preosteoclasts into mature osteoclasts.
Importantly, the inhibition of osteoclast differentiation is
counterbalanced by the action of OPG, which serves as the
soluble decoy receptor for RANKL, preventing its association
with RANK [57,58].
Imbalance of the OPG/RANKL/RANK axis may lead to
uncontrolled bone loss and various pathological conditions
[59], as observed in many diseases such as Paget’s disease
[60], rheumatoid arthritis [61], osteopenia [62] and Charcot
neuroarthropathy [63]. Ndip and colleagues found that serum
RANKL and OPG levels, as well as the RANKL/OPG ratio, are
increased in patients with Charcot neuroarthropathy when
compared to patients with diabetes or a healthy control group
[63]. The local inflammation and related increased expression
of the RANKL gene are associated with fractures and bone
destruction in Charcot neuroarthropathy [64]. In addition,
there is a correlation between increased bone resorption
and vascular calcification that may contribute to the develop-
ment of the disease [64–66].
The interplay between RANKL and OPG proteins controls
bone resorption and formation. However, other factors, such
as advanced glycation end products (AGE), reactive oxygen
species (ROS) and cytokines, influence this process and may
contribute to the development of Charcot neuroarthropathy
(as reviewed in [67]). Hyperglycaemia stimulates the forma-
tion of AGEs, and interplay between impaired AGE defence,
bone turnover and bone quality has been observed in Charcot
neuroarthropathy [68]. Patients with Charcot neuroarthropa-
thy display reduced levels of circulating soluble receptor of
advanced glycation end products (sRAGE), increased serum
osteocalcin, a marker of bone formation, and reduced calca-
neus bone stiffness. It is hypothesised that low levels of
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hyperglycaemia. Excess AGE may accumulate in tissues such
as tendons, bone or cartilage, where it may increase the pro-
duction of RAGE, which may in turn enhance RANKL activa-
tion leading to increased osteoclastogenesis, predisposing
the bone to fracture. Bone resorption by osteoclasts is also
stimulated by either TNF-a or RANKL, which upregulate the
expression of RANK and promote osteoclast differentiation
in vitro [69].
6.2. Association of OPG and RANKL variants with Charcot
neuroarthropathy
Different studies suggest the involvement of genetic factors
associated with OPG and RANKL variants in the development
of various skeletal system diseases with underlying osteope-
nia [70–72]. There are reports of an association of Charcot
neuroarthropathy with variants of OPG, RANKL and RANK
genes.
The OPG gene variants 245T>G, 1181G>C and 1217C>T have
been reported to be associated with Charcot neuroarthropa-
thy, but the allele frequencies at specified loci differ between
studies. Pitocco and colleagues found a positive association
with G alleles for both the OPG 1181G>C and 245T>G variants
in Italian patients with Charcot neuroarthropathy when com-
pared to patients with diabetic neuropathy and healthy con-
trols [73]. Subjects with diabetes and neuropathy with CC/
TT genotypes had an approximately six-fold lower risk of
Charcot neuroarthropathy. In a Polish population, for both
1217C>Tand 245T>G OPG gene variants, a positive correlation
between TT genotypes and Charcot neuroarthropathy was
found [74]. The TT genotype at these residues increased the
risk of developing Charcot neuroarthropathy by more than
three times. Polish patients with Charcot neuroarthropathy
had the CC genotype with the OPG 1181C>G variant almost
two times more often than patients with diabetic neuropathy
or diabetes. Studies involving larger groups of patients seem
to confirm these observations. In particular, a positive corre-
lation between the 245T>G OPG gene variant and TT genotype
with the development of Charcot neuroarthropathy was
observed [75]. It appears that the 1181G>C variant of the
OPG gene, which might be a potential marker of Charcot neu-
roarthropathy, is a marker specific to this complication alone.
The allele and genotype frequencies of RANKL 290C>T,
643C>Tand 693G>C variants also differ between patients with
Charcot neuroarthropathy, neuropathy and diabetes [74]. The
T alleles in RANKL 290C>T and 643C>T and the C allele in
693G>C have been found to occur more frequently in patients
with neuropathy and Charcot neuroarthropathy. This was
correlated with an increased frequency of the corresponding
homozygotes in groups with neuropathy and Charcot neu-
roarthropathy (TT for 290C>T and 643C>T, and CC for
693G>C), and these genotype frequencies differed signifi-
cantly from those observed in the diabetes group. No signifi-
cant changes in genotype and allele frequencies were
observed between groups for two variants of the RANK gene
(421C>T and 575C>T) [74].
An association between OPG 245T>G and OPG 1217C>T, as
well as between RANKL 290C>T and 693G>C variants, was
found in patients with Charcot neuroarthropathy, and thelinkage disequilibrium was the highest between these vari-
ants [74]. Based on similarities in their gene variant profiles,
the analysed group of patients was divided into three clusters
that differ in regard to the proportion of cases with diabetes,
neuropathy and Charcot neuroarthropathy: cluster 1 con-
tained mostly patients with diabetes, cluster 2 contained sim-
ilar proportions of patients with neuropathy and Charcot
neuroarthropathy, and cluster 3 consisted of about 50% of
patients with Charcot neuroarthropathy [74].
6.3. Serum OPG and RANKL levels in Charcot
neuroarthropathy
Serum levels of the RANKL and OPG proteins are increased in
patients with Charcot neuroarthropathy [63,74] and neuropa-
thy [74] and the RANKL/OPG ratio is higher in patients with
Charcot neuroarthropathy [46,63,74] than in patientswith dia-
betes or healthy controls. Jansen and colleagues observed that
the RANKL/OPG ratio was about three-fold higher in the Char-
cot group when compared to patients with diabetes without
this condition and after few years of standard treatment. As
the acute Charcot neuroarthropathy settled, the RANKL/OPG
ratio decreased by approximately seven timeswhen compared
to the baseline ratio [46]. These authors suggested that the
RANKL/OPG ratio is only elevated in the acute phase of Char-
cot neuroarthropathy. However, amore detailed study on a lar-
ger group of patients by Bruhn-Olszewska and colleagues
revealed that the RANKL/OPG serum ratio is much higher in
patients with neuropathy than patients with Charcot neu-
roarthropathy [74]. These authors suggested that an increased
level of RANKL is specific for neuropathy, and is probably the
key factor involved in bone loss. Interestingly, studies per-
formed by two independent groups demonstrated that the
OPG level is higher in patients with Charcot neuroarthropathy
when compared to patients with diabetes, and postulated the
hypothesis that OPG production is stimulated in response to
elevated levels of RANKL, likely to counterbalance its effect
on bone loss [63,74]. Increased serum levels of RANKL in
patients with Charcot neuroarthropathy have also been
demonstrated to promote osteogenic differentiation and the
mineralisation of vascular smooth muscle cells (VSMCs)
in vitro [63]. These studies support the hypothesis that RANKL
is not only involved in osteolysis, but also in the vascular cal-
cification associated with Charcot neuroarthropathy.
Despite the associations between the studied genetic vari-
ants, the available data indicate that the pathogenesis of
Charcot neuroarthropathy is multifactorial. Petrova and col-
leagues have recently shown that osteoclasts from subjects
with Charcot neuroarthropathy are characterised by an
increased reaction to RANKL when compared to osteoclasts
obtained from patients with diabetes (but not Charcot neu-
roarthropathy) and healthy controls [76]. RANKL-mediated
osteoclastic resorption in vitro is modulated by TNF-a [69,77].
Expression of this proinflammatory cytokine on monocytes
of patients with Charcot neuroarthropathy was found to be
increased when compared to patients with diabetes who did
not develop this complication [78]. The same authors also
observed that serum concentrations of TNF-a and IL-6 were
significantly higher in people with Charcot neuroarthropathy
than in people with and without diabetes. On follow up, there
Table 1 – Summary of the role of genetic factors and monocyte-to-osteoclast differentiation in Charcot neuroarthropathy
pathogenesis.
Factor or process Characteristics and possible role in the
pathogenesis of Charcot neuroarthropathy
Reference
Genetic factors RANKL/OPG variation
& Association of OPG 245T>G, 1181G>C and
1217C>T variants with Charcot
neuroarthropathy
& Association of RANKL 290C>T, 643C>T
and 693G>C variants with Charcot
neuroarthropathy
& Increased serum RANKL and OPG levels
in both patients with diabetic neuropa-





& Increased level of microparticles from
monocytes of patients with Charcot
neuroarthropathy
& High content of inflammatory cytokines,
i.e. G-CSF, GM-CSF, IL-1-ra, IL-2 and IL-16




& Differential expression of circulating








& Differential methylation of genes in cir-
culating monocytes of patients with
Charcot neuroarthropathy: e.g. HMGA1
and MAPK11
& Differential gene expression in circulat-
ing monocytes due to methylation
changes, e.g. PPP2R5D, POC1A and FOSB
& Migration during monocyte-to-osteo-
clast differentiation
& Regulation of inflammatory pathways
[79]
6 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 6 ( 2 0 2 0 ) 1 0 8 3 3 7was a significant reduction in the concentration of these
cytokines at resolution, suggesting that these markers may
be useful in the assessment of disease activity [51].6.4. Monocyte-to-osteoclast differentiation in acute
Charcot neuroarthropathy
The osteoclasts responsible for bone resorption differentiate
from monocytes. Several studies have demonstrated that
gene methylation in monocytes, monocyte-derived micropar-
ticles or microRNAs (miRNAs) can affect monocyte-to-
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 6 ( 2 0 2 0 ) 1 0 8 3 3 7 7osteoclast differentiation, and may therefore play an impor-
tant role in the development of Charcot neuroarthropathy.
Recent whole-methylome studies have identified over a hun-
dred genes that are differentially methylated in circulating
monocytes isolated from patients with Charcot neu-
roarthropathy compared to patients with diabetes [79]. In
patients with Charcot neuroarthropathy, most of these genes
were found to be hypermethylated. More importantly, about
15% of the differentially methylated genes include genes that
could be directly or indirectly involved in the differentiation
of monocytes into osteoclasts, with HMGA1 and MAPK11
genes as the strongest candidates. The same study also
demonstrated an association between DNA methylation and
gene expression in patients with Charcot neuroarthropathy.
The PPP2R5D gene was both hypermethylated and overex-
pressed in monocytes from patients with Charcot neu-
roarthropathy. Several differentially methylated genes were
found to have an effect on other expression-associated genes
including POC1A and FOSB genes, which are known to be
involved in bone-related disorders and in bone formation.
Microparticles (also known as microvesicles) are small,
membranevesicles that are released fromcells underdifferent
physiological and pathological conditions. Different patterns
of circulating microparticles have been detected in patients
with type 1 or type 2 diabetes and in patients with diabetic
complications [80]. In patientswith Charcot neuroarthropathy,
microparticles from monocytes, but not platelets, are present
at higher amounts when compared to patients with diabetic
neuropathy or healthy controls [81]. Increased levels of cytoki-
nes such as G-CSF, GM-CSF, IL-1-ra, IL-2 and IL-16 were
detected only inmicroparticles from patientswith acute Char-
cot neuroarthropathy, but levels in the serum were not ele-
vated. Those cytokines are linked to pathways that are
involved in osteoclast formation. Moreover, the incubation of
monocytes from healthy controls with microparticles derived
from patients with Charcot neuroarthropathy increased their
differentiation into osteoclasts in vitro [81].
Circulating miRNAs may also play a role in the develop-
ment of Charcot neuroarthropathy, presumably by the regula-
tion of monocyte-to-osteoclast differentiation. MiRNAs are
small, non-coding RNAs present in cells that act as post-
transcriptional regulators of gene expression. MiRNAs are
also detected in serum and extracellular fluids, which are ter-
med circulating miRNAs and extracellular miRNAs, respec-
tively [82]. Comparison of the serum levels of mature
human miRNAs revealed differential expression of several
miRNAs between patients with acute Charcot neuroarthropa-
thy, patients with diabetes and neuropathy and those without
neuropathy [83]. Deregulation of seven miRNAs (miR19a-3p,
miR101-3p, miR144-3p, miR16-2-3p, miR16-5p, miR362-3p
and miR30e-5p) was found to be strongly correlated with
Charcot neuroarthropathy. The authors also identified that a
number of circulating miRNAs that were differentially
expressed between Charcot neuroarthropathy and neuropa-
thy groups could be involved in the differentiation of mono-
cytes into osteoclasts.
7. Concluding remarksEffective prevention of the serious consequences of diabetes
is still a challenge. Identifying reliable and repeatable genetic
markers of Charcot neuroarthropathy would help to identify
patients who are at higher risk of developing this condition
soon after they are diagnosed with diabetes. Genetic factors
play an important role in the development of Charcot neu-
roarthropathy. Recent observations suggest the involvement
of OPG and RANKL gene variants in the development of
osteopenia and vascular calcification that are characteristic
of Charcot neuroarthropathy (Table 1). Multiple variant sites
within these two genes could potentially be used as predictive
markers of Charcot neuroarthropathy. Along with genetic
markers, profiles of inflammatory cytokines in circulating
microparticles or serum levels of specific miRNAs could be a
simple and convenient screening tool to diagnose or predict
the risk of Charcot neuroarthropathy development; however,
studies on larger cohorts are necessary to confirm their use-
fulness as a diagnostic tool. As monocytes appear to be
directly involved in the pathogenesis of Charcot neu-
roarthropathy (Table 1), further studies of the monocyte-to-
osteoclast differentiation process may lead to a better under-
standing and perhaps early prevention of this condition.
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